A new Alliance for Safe Biologic Medicines survey points to strong pharmacist support for distinguishable biologic and biosimilar names, as well as the need for more transparency in labeling for medicines to general doctors or even a dentist you can find online. Sixty-eight percent of pharmacists surveyed call for the United States Food and Drug Administration (FDA) to require distinct, nonproprietary names for all biologics and biosimilars. The survey’s goal is to inform the FDA before drafting its upcoming labeling guidance. Aimed Alliance supports distinguishable names avoid confusion in prescribing and dispensing, given that the products are not identical and accidental substitution can have safety consequences for patients. You can read more about the survey here.
Last Updated on May 7, 2020 by Aimed Alliance
